Highest-materiality recent filing
Medpace reports Q2 2026 results; no specific figures in filing
Press release issued on July 22, 2026 for Q2 2026 results.
Appoints Brad W. Hansman as EVP, Operations effective June 1, 2026
Brad W. Hansman appointed EVP, Operations effective June 1; will serve as co-principal operating officer with Susan E. Burwig.
Shareholders approved removal of supermajority voting requirements (24.3M for, 95k against); effective May 18, 2026.
Jesse Geiger to resign as President effective May 31, 2026; not due to disagreement.
Medpace reports Q4/FY2025 results; specific figures unavailable from filing
Press release issued Feb 9, 2026 for quarter and year ended Dec 31, 2025.
Medpace reports Q3 2025 earnings; press release unavailable for detail extraction
Issued press release on October 22, 2025 announcing financial results for three and nine months ended September 30, 2025.
Medpace reduces credit line to $10M; Q2 2025 earnings announced, figures not provided
Amendment No. 9 to credit facility reduces line of credit to $10M, executed July 17, 2025.
Elected August J. Troendle (21.2M for) and Dani S. Zander (25.9M for) as Class III directors.
Board approved $1.0B increase to stock repurchase program; timing based on market conditions.
Medpace extends revolving credit facility expiration to March 31, 2026
Amendment No. 7 extends the revolving credit note expiration date to March 31, 2026, representing a one-year extension.
Medpace reports Q4/FY24 earnings (no specifics shown) and boosts buyback by $600M
Issued press release for Q4 and FY2024 results; no financial figures included in filing.
Medpace reports Q3 2024 results; details not available in extracted exhibit text
Press release dated October 21, 2024, issued under Item 2.02.
Medpace Holdings announces Q2 2024 financial results on July 22, 2024
Medpace Holdings issued a press release on July 22, 2024, reporting financial results for the three and six months ended June 30, 2024.
Medpace director Ashley Keating resigns; Dr. Dani Zander elected to board
Ashley M. Keating resigned from the Board effective June 30, 2024, with no disagreement on operations, policies, or practices.
Medpace shareholders approve board declassification; annual director elections start 2025
Stockholders approved amendment to phase out classified board; directors elected annually beginning at 2025 annual meeting.
Medpace reports Q1 2024 results; exhibit not provided, no specific data available
Press release filed as Exhibit 99.1 for three months ended March 31, 2024.
Medpace reduces revolving credit facility from $150M to $10M, extends to March 2025
Line of credit reduced to $10M from $150M; expiration extended to March 31, 2025.
Medpace announces Q4 and FY2023 results; no specific figures available in filing text
Press release posted on company website and furnished as Exhibit 99.1, but exhibit text not included in prompt.
Medpace Q3 2023 earnings: press release issued without specific numbers in excerpt
Medpace issued a press release on October 23, 2023, announcing Q3 2023 financial results.
Medpace Q2 revenue $469.4M (+27% YoY), EPS $2.35 (+62%); raises FY 2023 guidance
Revenue $469.4M (+27.4% YoY), net income $75.6M (+62.5%), diluted EPS $2.35.
Medpace stockholders elect three directors, ratify auditor, approve say-on-pay
Elected Brian T. Carley, Femida H. Gwadry-Sridhar, and Robert O. Kraft as Class I directors until 2026.
Medpace announces Q1 2023 results; press release content not included in filing extract
Press release dated April 24, 2023, furnished as Exhibit 99.1 but not provided in the supplied text.
Medpace reduces revolving credit line to $150M, extends facility to March 2024
Amendment No. 5 with PNC Bank cuts the revolving credit facility from $250M to $150M.
Medpace Q4/FY2022 earnings release; detailed results not available in filing text
Medpace issued a press release on February 13, 2023 for Q4 and full year 2022 results.
Medpace appoints Dr. Femida H. Gwadry-Sridhar as new Class I director
Dr. Gwadry-Sridhar appointed to Board effective Jan 16, 2023, filling a Class I vacancy.
Director Thomas C. King resigns from Medpace Board effective Dec 31, 2022
Thomas C. King notified Medpace of his resignation from the Board on December 31, 2022.
Medpace Q3 earnings released; Board authorizes $500M share buyback
Board authorized share repurchases of up to $500M of common stock on Oct 21, 2022.
Medpace reports Q2 2022 revenue $351.2M (+26.2% YoY), diluted EPS $1.46 vs $1.06
Revenue $351.2M, up 26.2% YoY; constant currency organic growth 27.7%.
Medpace Board approves $50M increase to share repurchase program
Board of Directors approved $50M increase to existing stock repurchase program on June 10, 2022.
Medpace boosts buyback by $60M; retired 1.6M shares (~5% of float) in past month
Board approved $60M increase to existing stock repurchase program on May 25, 2022.
Directors August Troendle and Ashley Keating elected to Class III board; Keating received 12,863,441 for vs. 17,722,711 withheld.
Medpace Q1 revenue up 27.3% to $330.9M; EPS $1.69 vs $1.14 YoY
Revenue $330.9M, +27.3% YoY; constant-currency organic growth +28.1%.
Medpace increases credit facility to $250M and expands share buyback by $200M
Amendment No. 4 raises line of credit from $50M to $250M with PNC Bank, maturing March 31, 2023.
Q4 2021 GAAP net income $50.0M ($1.32 EPS) vs $50.9M ($1.35 EPS) prior year; net income margin 16.2%.
Medpace extends $50M credit facility to March 2023; adopts LIBOR replacement terms
Amendment extends revolving credit note expiration to March 31, 2023.
Medpace Q3 revenue $295.6M (+28.3%), EPS $1.29; net new awards $408M
Revenue $295.6M, up 28.3% YoY; net income $48.6M ($1.29 diluted EPS) vs $41.5M ($1.09) prior year.
Medpace appoints Jesse Geiger as President, Kevin Brady as CFO effective Aug 1
Jesse Geiger, formerly CFO and COO of laboratory ops, becomes President; August Troendle remains Chairman & CEO.
Medpace Q2 2021 revenue up 35.8% to $278.3M; net income $39.9M ($1.06 EPS)
Net new business awards of $387.6M (+52.5% YoY) produced a 1.39x book-to-bill ratio.
Medpace Holdings establishes Nominating and Governance Committee
Board created a Nominating and Governance Committee effective July 22, 2021.
Effective June 1, 2026, Medpace Holdings, Inc. (the “ Company ”) appointed Brad W. Hansman, age 43, to the position of Executive Vice President, Operations.
On June 28, 2024, Ashley M. Keating, a member of the Board of Directors (the “Board”) of Medpace Holdings, Inc. (the “Company”) notified the Company of her resignation, effective as of June 30, 2024.
The Board of the Company following a recommendation from the independent directors of the Board, unanimously approved that Dr. Dani S. Zander be elected to fill the Class III director vacancy on the Board of the Company, effective July 1, 2024
unanimously approved that Dr. Femida H. Gwadry-Sridhar be elected to fill the Class I director vacancy on the Board of the Company, effective January 16, 2023
On December 31, 2022, Thomas C. King, a member of the Board of Directors (the “Board”) of Medpace Holdings, Inc. (the “Company”) notified the Company of his resignation from the Board, effective as of December 31, 2022.
appointments of Jesse J. Geiger to the position of President
Kevin M. Brady to the position of Chief Financial Officer
Max materiality 0.80 · Median 0.50 · Most common event earnings